timothy sykes logo
CDTX’s Meteoric Rise: What’s Next? Thumbnail
ADD US ONG Google News

CDTX’s Meteoric Rise: What’s Next?

TIM SYKES•UPDATED NOV. 14, 2025, 5:06 PM ET
Reviewed by Bryce Tuohey Fact-checked by Matt Monaco

Cidara Therapeutics Inc. stocks have been trading up by 105.23 percent, driven by positive sentiment surrounding FDA designations.

  • Cidara is closing in on an acquisition deal with pharma giant Merck, following intense competition and interest, signaling a promising buyout.

  • The company’s pivotal Phase 3 enrollment for CD388 remains on track, leading RBC Capital to increase its price target from $137 to $145 with an Outperform rating.

Candlestick Chart

Live Update At 17:05:27 EST: On Friday, November 14, 2025 Cidara Therapeutics Inc. stock [NASDAQ: CDTX] is trending up by 105.23%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

A Quick Look at Recent Earnings

when people begin their trading journeys, it’s essential to remind them that the market operates in cycles. Even seasoned traders sometimes get caught up in the excitement of trends, leading them to make rash decisions. As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.” Not every trade needs to be pursued instantaneously. Taking a step back allows for more strategic decision-making, ensuring they aren’t swayed purely by emotion. Remembering this can prevent costly mistakes in an ever-fluctuating market.

Cidara Therapeutics’ recent earnings report showed a challenging picture. The company incurred a significant net income loss of $83.23M for Q3. Despite the financial struggles, there’s noticeable progress in their research and trials. The ongoing development of CD388 is crucial, saying a lot about their efforts to revolutionize flu prevention.

Their current ratio of 4.6 indicates strong short-term liquidity, but profitability margins remain under pressure with a pretax profit margin of -258.9%. This underscores the significant obstacles still facing the company. However, their debt-to-equity remains at zero, showing no leverage in terms of long-term debt, a position does reduce financial strain somewhat.

In the competitive pharmaceutical industry, Cidara’s balance sheet reflects assets totaling $518.65M and equity pegged at $422.39M. This paints a picture of resilience, demonstrating both the potential growth from recent innovations and the pressures from ongoing operational expenses.

Market Implications of the Recent News

The news of successful trial outcomes for CD388 has been a key driver in Cidara’s stock momentum. Often, successes in clinical trials lead to bullish market reactions due to the future revenue potential of new drugs. Investors see these results as a harbinger of potential breakthroughs that could generate significant financial returns.

More Breaking News

Moreover, the potential acquisition by Merck highlights a strategic interest from bigger players in Cidara’s technology. If the deal proceeds, it may provide not just cash flow but also validity to Cidara’s innovative approaches, adding more wind beneath their wings. RBC Capital’s increase in their price target aligns with these developments, suggesting optimism around future funding and commercial success.

Financial Findings and Future Speculations

Digging deeper into the financial performance, significant investments in R&D underscore the firm’s focus on innovation. A free cash flow reaching -$40.62M indicates high cash burn typical for biotech firms in heavy research phases. Yet, its substantial cash reserves of $420.02M highlight ongoing capabilities to fuel future phases of their clinical studies.

RBC Capital’s re-rating, alongside Morgan Stanley’s Overweight position, points to a positive forecast among analysts, driven primarily by the promising trial results and potential buyout news. The enigmatic rise of Cidara is a classic case of high-risk, high-reward investing.

What This Means for Investors?

For those navigating the stock market seas, Cidara seems to be at a pivotal moment. Such firms often face volatility. They represent transformational potential, which could see them evolve from underdogs into industry leaders. This makes it both an exciting opportunity and a precarious trading choice.

Traders eyeing Cidara must weigh the optimism around its scientific breakthroughs and potential acquisition against the backdrop of financial challenges and market uncertainties. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.” Cidara’s recent stock performance is a testament to the high stakes involved in biotech trading, reflecting both the risks and impressive upside potential. For prudent retail traders, staying informed about trial updates and acquisition news will be essential to navigate these rapid financial tides effectively. The journey of Cidara in the competitive landscape is like a captivating movie – thrilling, full of unexpected turns, and always leaving you at the edge of your seat.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading CDTX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”